Today 193 countries will sign a landmark declaration agreeing to combat the biggest risk to modern medicine – antimicrobial resistance – at the United Nations General Assembly in New York.
The University of Cape Town (UCT)’s Drug Discovery and Development Centre, H3D, has identified a new potent anti-malarial development candidate with potential for both treatment and prevention of malaria
Maison de la Paix, Chemin Eugène-Rigot 2, 1202 Geneva
Please join us at this year’s World Health Assembly for a conversation with product developers on developing and scaling essential
health technologies. This moderated panel discussion will explore the current challenges of incentivising the development of innovative technologies that address the burden of disease globally, specifically poverty related and neglected diseases, while ensuring they are accessible to those most in need. Representatives from industry, academia, and nonprofit product development partnerships will debate the most significant barriers to access, and share successes, challenges, and lessons learned from a product developer’s perspective.
The University of Cape Town’s Drug Discovery and Development Centre, H3D, has entered into a strategic partnership with Janssen Pharmaceutica N.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), aimed at jointly identifying and addressing the unique issues of advanced drug development in Africa.
The Universities of Dundee (Scotland) and Cape Town (South Africa) have linked up with the industrial expertise of the pharmaceuticals division of Germany’s Bayer (BAYN: DE), in an effort to develop critically needed new treatments for tuberculosis (TB). The collaboration combines some of the world’s best knowledge on TB biology, drug discovery and medicinal chemistry, with access to an industrial library of chemical compounds.
The recent launch of H3D’s state-of-the-art, R22 million medicinal chemistry laboratory marks a new chapter in the university’s drug discovery programme.
Darmstadt, Germany, November 19, 2015 – Merck, a leading science and technology company, today announced that a research agreement has been signed with the University of Cape Town (UCT) South Africa to co-develop a new R&D platform aimed at identifying new lead programs for potential treatments against malaria, with the potential to expand it to other tropical diseases.
Kelly didn’t have the easiest start to his academic career. After attending three different primary schools, he had to retake his final examinations in order to attend secondary school in Kasama, the capital of the Northern Province of Zambia. At the end of school, he was unsuccessful in his application to study accounting at university and was forced to take a step back and reconsider his options. In this time, Kelly remembered his fascination with chemical reactions and colour changes at school and decided to study chemistry instead.
Le paludisme est un fléau qui déchire l’Afrique depuis des décennies. Les compagnies pharmaceutiques annoncent régulièrement des avancées dans la recherche d’un vaccin. En Afrique du Sud, des scientifiques pensent avoir trouvé un raccourci vers un traitement efficace.
Dr Greg Basarab has just joined H3D as a Principal Research Officer (Medicinal Chemistry Programme Lead), with effect from June 2015. Dr Basarab comes with more than 15 years’ experience in the pharmaceutical industry, with just over 5 years spent as a Principal Scientist II/Associate Director and the 10 years prior to that as Principal Scientist I at AstraZeneca R&D Boston Infection Innovative Medicines Department in the USA.